Making earlier cancer detection a routine part of medical care
Total revenue excluding COVID testing grew 20% in 3Q22
Total revenue
(excluding COVID testing)
$426M
+20%
$512M
Screening revenue
■ Cologuard®
■ Prevention Genetics
+29%
$280M /
$361M
$351M
3Q21
3Q22
3Q21
Cologuard revenue includes immaterial revenue from Biomatrica products and Oncoguard® Liver;
Precision Oncology includes laboratory service revenue from global Oncotype® products and therapy selection products, including
Oncomap™ and OncomapTM ExTra, formerly known as Oncotype MapTM and GEM ExTra®, respectively;
Precision Oncology revenue grew 9% excluding a $2.9M FX headwind and the divestiture of the Oncotype DX Prostate test
Note: revenue charts are not to scale
EXACT SCIENCES
3Q22
Precision Oncology revenue
Domestic
International
$145M
3Q21
+4%
$151M
3Q22
4View entire presentation